Yes, attraction is not that simple. You can’t put some criteria in a table and tick them off.
True. But neither should responsible people ignore studies on some of the adverse side effects of the pill. Not saying you do, and doubt you do. But the following is additional information which you might find of interest.
I did not come in here to critique any particular woman’s preferences for males or vice versa. But it does seem to me that people tend to be awfully sanguine about very powerful drugs that have wide-ranging effects. As I mentioned before, when potential environmental effects (I am far from being an environmentalist myself) seem to be demonstrated from very indirect and smallish exposures, should we be less concerned about those who actually ingest those chemicals?
Some of the following doesn’t have to do with the pheromone phenomenon, but if manufactured estrogen compounds can do all of this, shouldn’t we be tremendously concerned about the array of effects of heavy usage? And further, should we not give some consideration to the possibility that “the way God made us” might just be the proper way for us to remain in lieu of routinely altering our body chemistry for no therapeutic purpose? Is “not worrying about having sex” really worth all the hazards?
“£30bn bill to purify water system after toxic impact of contraceptive pill”
guardian.co.uk/environmen…raceptive-pill
“[progestins] not only affect the developing embryo but also have been shown to alter adult ovarian function by targeting steroidogenesis. Hence, not only do these agents have the potential to disrupt reproductive cyclicity and/or the normal levels of ovarian steroid hormone production that are required to support implantation and the early stage of pregnancy, but these compounds may also cause transgenerational effects by targeting oocyte maturation and maternal sex chromosomes. As described, there are fundamental differences in developmental processes that control gonadogenesis in males and females.”
Developmental exposure to environmental endocrine disruptors: Consequences within the ovary and on female reproductive function
Mehmet Uzumcu, Rob Zachow
Reproductive Toxicology, Volume 23, Issue 3, April–May 2007, Pages 337–352
“Thus, when high estrogen oral contraception, considered to be a risk factor for breast cancer (112), is superimposed on a hypoglycemic elevation of IGF-II, breast cancer is a possible con- sequence. This increased risk for breast cancer may also, in part, be caused by an estrogen-induced elevation of HDL cholesterol which the high progestin contraceptive pill lowers (112). Males with excessive ethanol intake may also be equally susceptible to developing malignant tumors since ethanol is associated with an elevation of estrogen (28). But while breast cancer and other forms of cancer such as: gastric carcinoma (113); colorectal cancer (114); endometrial cancer (115); adrenocortical tumors (116); and meningioma (117) are associated with hypoglycemia and overexpression of IGF-II; lymphoma (118), lung cancer (119,120), and colorectal adenomas (121) are all associated with a lowered HDL profile.”
The estrogen connection: The etiological relationship between diabetes, cancer, rheumatoid arthritis and psychiatric disorders
R.J. Holden
Medical Hypotheses, Volume 45, Issue 2, August 1995, Pages 169–189
“Since it is now well-established that estrogen can cause epigenetic changes, it is reasonable to design experiments that ask whether the side effects associated with the use of synthetic estrogens are fully reversible after cessation of the drug. For example it has been shown that the Combined Oral Contraceptive Pill (COCP) can cause sexual dysfunction by elevating levels of Sex Hormone Binding Globulin (SHBG). SHBG binds to sex hormones, including testosterone, rendering them unavailable. Even after women stop taking the COCP, SHBG levels remain elevated and no reliable data exists to predict when they will diminish. Indeed, it has already been suggested that this is a persistent epigenetic effect on SHBG gene expression.”
Epigenetic side-effects of common pharmaceuticals: A potential new field in medicine and pharmacology
Antonei B. Csoka, Moshe Szyf
Medical Hypotheses, Volume 73, Issue 5, November 2009, Pages 770–780
International Agency for Research on Cancer (IARC) Monograph Preamble on the Evaluation of Carcinogenic Risks to Humans (page 2):
monographs.iarc.fr/ENG/Classi…GroupOrder.pdf
(Group 1 Carcinogenic to humans (107 agents))